Published in Can Fam Physician on September 01, 2009
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2007) 6.57
Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics (2001) 5.30
Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics (2000) 5.21
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 4.58
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry (2002) 4.57
Sudden death and use of stimulant medications in youths. Am J Psychiatry (2009) 4.33
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry (2001) 3.87
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry (2008) 3.34
Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med (2005) 2.27
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr (2001) 2.20
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry (2007) 2.03
Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics (2008) 1.72
The child with ADHD: using the AAP Clinical Practice Guideline. American Academy of Pediatrics. Am Fam Physician (2001) 1.49
Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm (2007) 0.88
Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD). Essent Psychopharmacol (2005) 0.83
Integrating pharmacists into primary care teams: barriers and facilitators. Int J Pharm Pract (2013) 0.92
Opioids for chronic noncancer pain in the elderly: an osteoarthritis case. Can Fam Physician (2011) 0.88
Rate versus rhythm control in atrial fibrillation. Can Fam Physician (2013) 0.86
Taking the stress out of acne management. Can Fam Physician (2009) 0.83
A brief overview of academic detailing in Canada: Another role for pharmacists. Can Pharm J (Ott) (2012) 0.82
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in chronic heart failure. Ann Intern Med (2005) 0.78
Behaviour management in dementia. Can Fam Physician (2011) 0.77
Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II): Implementation of a systematic case-finding process for patients with uncontrolled risk factors. Can Pharm J (Ott) (2013) 0.77
Diabetes in the frail elderly: individualization of glycemic management. Can Fam Physician (2012) 0.77
Targeting success in heart failure: evidence-based management. Can Fam Physician (2010) 0.75
Pharmacologic management of essential tremor. Can Fam Physician (2010) 0.75
Taking the stress out of insulin initiation in type 2 diabetes mellitus. Can Fam Physician (2009) 0.75
Navigating the complexity of ulcerative colitis: challenging case example. Can Fam Physician (2011) 0.75
Taking the stress out of treating erectile dysfunction. Can Fam Physician (2010) 0.75
Approach to the management of idiopathic hirsutism. Can Fam Physician (2012) 0.75
Taking the stress out of managing gout. Can Fam Physician (2009) 0.75
Funding for continuing medical education. CMAJ (2008) 0.75
Drug comparison charts. Detailed, objective, comparative drug information. Can Fam Physician (2004) 0.75